Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion

被引:52
作者
Coffill, Cynthia R. [1 ]
Muller, Patricia A. J. [2 ]
Oh, Hue Kian [1 ]
Neo, Suat Peng [1 ]
Hogue, KellyA. [1 ]
Cheok, Chit Fang [3 ]
Vousden, Karen H. [2 ]
Lane, David P. [3 ]
Blackstock, Walter P. [1 ]
Gunaratne, Jayantha [1 ]
机构
[1] Inst Mol & Cell Biol, Quantitat Prote Grp, Singapore 138673, Singapore
[2] Beatson Inst Canc Res, Glasgow G61 1BD, Lanark, Scotland
[3] ASTAR, Lab P53, Singapore 138648, Singapore
关键词
HB-EGF; interactome; invasion; mutant p53; SILAC; LI-FRAUMENI-SYNDROME; IARC TP53 DATABASE; GROWTH-FACTOR; CELL-CULTURE; AMINO-ACIDS; PROTEIN INTERACTIONS; GAIN; CANCER; MUTATION; ACTIVATION;
D O I
10.1038/embor.2012.74
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The invasiveness of tumour cells depends on changes in cell shape, polarity and migration. Mutant p53 induces enhanced tumour metastasis in mice, and human cells overexpressing p53R273H have aberrant polarity and increased invasiveness, demonstrating the 'gain of function' of mutant p53 in carcinogenesis. We hypothesize that p53R273H interacts with mutant p53-specific binding partners that control polarity, migration or invasion. Here we analyze the p53R273H interactome using stable isotope labelling by amino acids in cell culture and quantitative mass spectrometry, and identify at least 15 new potential mutant p53-specific binding partners. The interaction of p53R273H with one of them-nardilysin (NRD1)-promotes an invasive response to heparin binding-epidermal growth factor-like growth factor that is p53R273H-dependant but does not require Rab coupling protein or p63. Advanced proteomics has thus allowed the detection of a new mechanism of p53-driven invasion.
引用
收藏
页码:638 / 644
页数:7
相关论文
共 35 条
[1]   A Mutant-p53/Smad Complex Opposes p63 to Empower TGFβ-Induced Metastasis [J].
Adorno, Maddalena ;
Cordenonsi, Michelangelo ;
Montagner, Marco ;
Dupont, Sirio ;
Wong, Christine ;
Hann, Byron ;
Solari, Aldo ;
Bobisse, Sara ;
Rondina, Maria Beatrice ;
Guzzardo, Vincenza ;
Parenti, Anna R. ;
Rosato, Antonio ;
Bicciato, Silvio ;
Balmain, Allan ;
Piccolo, Stefano .
CELL, 2009, 137 (01) :87-98
[2]   A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling [J].
Blagoev, B ;
Kratchmarova, I ;
Ong, SE ;
Nielsen, M ;
Foster, LJ ;
Mann, M .
NATURE BIOTECHNOLOGY, 2003, 21 (03) :315-318
[3]   A Quantitative Proteomics Analysis of Subcellular Proteome Localization and Changes Induced by DNA Damage [J].
Boisvert, Francois-Michel ;
Lam, Yun Wah ;
Lamont, Douglas ;
Lamond, Angus I. .
MOLECULAR & CELLULAR PROTEOMICS, 2010, 9 (03) :457-470
[4]   When mutants gain new powers: news from the mutant p53 field [J].
Brosh, Ran ;
Rotter, Varda .
NATURE REVIEWS CANCER, 2009, 9 (10) :701-713
[5]   MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification [J].
Cox, Juergen ;
Mann, Matthias .
NATURE BIOTECHNOLOGY, 2008, 26 (12) :1367-1372
[6]   Gain of function of mutant p53: The mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation [J].
Di Agostino, Silvia ;
Strano, Sabrina ;
Emiliozzi, Velia ;
Zerbini, Valentina ;
Mottolese, Farcella ;
Sacchi, Ada ;
Blandino, Giovanni ;
Piaggio, Giulia .
CANCER CELL, 2006, 10 (03) :191-202
[7]   GAIN OF FUNCTION MUTATIONS IN P53 [J].
DITTMER, D ;
PATI, S ;
ZAMBETTI, G ;
CHU, S ;
TERESKY, AK ;
MOORE, M ;
FINLAY, C ;
LEVINE, AJ .
NATURE GENETICS, 1993, 4 (01) :42-46
[8]   Elevated expression of p53 gain-of-function mutation R175H in endometrial cancer cells can increase the invasive phenotypes by activation of the EGFR/PI3K/AKT pathway [J].
Dong, Peixin ;
Xu, Zhujie ;
Jia, Nan ;
Li, Dajin ;
Feng, Youji .
MOLECULAR CANCER, 2009, 8
[9]   Activation of HER4 by heparin-binding EGF-like growth factor stimulates chemotaxis but not proliferation [J].
Elenius, K ;
Paul, S ;
Allison, G ;
Sun, J ;
Klagsbrun, M .
EMBO JOURNAL, 1997, 16 (06) :1268-1278
[10]  
Foulon T, 1997, ANN ENDOCRINOL-PARIS, V58, P357